GA-ASI Begins Demonstration Flights in Greece
10.12.2019 08:00:00 EET | Business Wire | Press release
Today General Atomics Aeronautical Systems, Inc. (GA-ASI) begins a series of demonstration flights using its MQ-9 Guardian Remotely Piloted Aircraft (RPA). The flights, being hosted by the Hellenic Air Force (HAF) and staged out of Larissa Air Base in Greece, showcase the maritime surveillance capabilities of the MQ-9, as well as the GA-ASI-developed Detect and Avoid (DAA) system.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191209005846/en/
GA-ASI's MQ-9 Guardian RPA at the Larissa Air Base in Greece ready to demonstrate maritime surveillance and Detect and Avoid (DAA) capabilities. (Photo: Business Wire)
“We appreciate the HAF’s support with our customer demonstrations,” said Linden Blue, CEO, GA-ASI. “GA-ASI is highlighting the maritime surveillance and civil airspace integration capabilities of our unmanned aircraft for our European customers. Our long-endurance RPA (25-40 hours per sortie, depending on configuration) will be on display and provide insight into the importance of maritime patrol, as well as showcase our DAA avionics system that will support our goal of flying RPA in civil airspace.”
The flight series is being performed for an audience of European country representatives.
“The HAF looks forward to seeing the results of this demonstration. In addition to defense capabilities, these aircraft provide maritime patrol and EEZ monitoring, border surveillance, support for search and rescue efforts, and over-watch of forest fire response efforts,” said an HAF official.
GA-ASI’s DAA system consists of an air-to-air radar integrated with Traffic Alert and Collision Avoidance System (TCAS II) and Automatic Dependent Surveillance-Broadcast (ADS-B). The system’s traffic surveillance and collision avoidance radar provides important safety features for the flight of a large Unmanned Aircraft Systems in controlled airspace.
The MQ-9 will also demonstrate a multi-mode maritime surface-search radar with Inverse Synthetic Aperture Radar (ISAR) mode, an Automatic Identification System (AIS) receiver, and High-Definition/Full-Motion Video sensor equipped with optical and infrared cameras. This sensor suite enables real-time detection and identification of surface vessels over thousands of square nautical miles. The featured Raytheon SeaVue surface-search radar provides continuous tracking of maritime targets and correlation of AIS transmitters with radar tracks.
GA-ASI is also partnering with SES, a leading satellite communications (SATCOM) operator and managed services provider, with over 70 satellites in Geostationary Orbit (GEO) and Medium Earth Orbit (MEO). SES will provide the GEO satellite connectivity that enables the MQ-9 to operate securely with a high capacity datalink, enabling real-time transmission of sensor data from the aircraft, and extending its effective operational range far beyond that of “line-of-sight” datalinks.
“With our global satellite fleet, SES has been supporting the critical needs of GA-ASI and their government customers who have operated these aircraft for close to two decades,” said Nicole Robinson, Senior Vice President, Global Government at SES Networks. “We are proud to support this demonstration effort for the Hellenic Air Force as part of our long-standing relationship with General Atomics.”
Hi-resolution images of MQ-9 Guardian are available to qualified media outlets from the GA-ASI and HAF media contact list. To follow events from the demo, go to ga-asi.com/European-Maritime-Demo.
About GA-ASI
General Atomics Aeronautical Systems, Inc. (GA-ASI), an affiliate of General Atomics, is a leading designer and manufacturer of proven, reliable Remotely Piloted Aircraft (RPA) systems, radars, and electro-optic and related mission systems, including the Predator® RPA series and the Lynx® Multi-mode Radar. With more than six million flight hours, GA-ASI provides long-endurance, mission-capable aircraft with integrated sensor and data link systems required to deliver persistent flight that enables situational awareness and rapid strike. The company also produces a variety of ground control stations and sensor control/image analysis software, offers pilot training and support services, and develops meta-material antennas. For more information, visit ga-asi.com.
Predator and Lynx are registered trademarks of General Atomics Aeronautical Systems, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191209005846/en/
Contact information
Steven Henden
General Atomics Aeronautical Systems, Inc.
+1 (858) 524-8101
ASI-MediaRelations@ga-asi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom